Table 1. Demographic and clinical characteristics of the patients with PH.
| Variable | Overall (n = 140) | Control (n = 41) | SSc (n = 19) | IPAH (n = 30) | SSc-PAH (n = 42) | SSc-PH-ILD (n = 8) |
| Age (mean ± SD years) | 53±13 | 45±12 | 55±10 | 52±12 | 60±13 | 61±11 |
| Gender n (%) | ||||||
| Female | 117 (83.6) | 34 (82.9) | 19 (100) | 25 (83.3) | 33 (78.6) | 6 (75.0) |
| Male | 23 (16.4) | 7 (17.0) | 0 (0) | 5 (16.7) | 9 (21.4) | 2 (25.0) |
| Race n (%) | ||||||
| African American | 20 (14.3) | 7 (17.1) | 0 (0) | 5 (16.7) | 8 (19.0) | 0 (0) |
| Asian | 4 (2.9) | 1 (2.4) | 0 (0) | 1 (3.3) | 1 (2.4) | 1 (12.5) |
| Caucasian | 115 (82.1) | 33 (80.5) | 19 (100) | 23 (76.7) | 33 (78.6) | 7 (87.5) |
| Hispanic | 1 (0.7) | 0 (0) | 0 (0) | 1 (3.3) | 0 (0) | 0 (0) |
| NYHA functional class n (% of the PAH subjects) | ||||||
| I | 9 (11.3) | NA | NA | 7 (23.3) | 2 (4.8) | 0 (0) |
| II | 39 (48.7) | NA | NA | 16 (53.3) | 22 (52.4) | 1 (12.5) |
| III | 30 (37.5) | NA | NA | 6 (20.0) | 17 (40.4) | 7 (87.5) |
| IV | 2 (2.5) | NA | NA | 1 (3.3) | 1 (2.4) | 0 (0) |
| NA (# for which value is not available) | 60 (the non-PAH subjects) | 41 | 19 | 0 | 0 | 0 |
| 6MWD (mean ± SD (# missing values)) | 1174±395 (64) | NA | NA | 1383±392 (3) | 1091±340 (1) | 891±378 (0) |
| RA mean (mean ± SD (# missing values)) | 7.7±4.2 (61) | NA | NA | 7.7±4.2 (0) | 7.9±4.4 (1) | 7.5±3.8 (0) |
| CI (mean ± SD (# missing values)) | 2.66±0.72 (61) | NA | NA | 2.61±0.69 (0) | 2.66±0.74 (1) | 2.88±0.80 (0) |
| PVRI (mean ± SD (# missing values)) | 1062±573 (61) | NA | NA | 1214±573 (0) | 955±556 (1) | 1042±610 (0) |
| PA saturation (mean ± SD (# missing values)) | 66.7±8.2 (65) | NA | NA | 66.1±9.1 (2) | 67.1±8.0 (2) | 66.9±6.7 (1) |
Except where indicated otherwise, values are the number (%).